In this article, we will explore the topic of Leu-enkephalin from different perspectives and with a broad focus. Leu-enkephalin is a topic that has generated great interest and debate in today's society, and its relevance cuts across different areas of daily life. Throughout this article, we will examine the different aspects that make up Leu-enkephalin, analyzing their impact in different contexts and their influence on society in general. From its origin to its current evolution, passing through its implications in the personal, professional and social sphere, we will delve into the complexity of Leu-enkephalin and its multiple facets. Through this analysis, we seek to offer a comprehensive and enriching vision that invites reflection and debate about Leu-enkephalin and its place in our contemporary reality.
| Names | |
|---|---|
| IUPAC name
(2R)-2-amino]acetyl]
| |
| Other names
enkephalin; enkephalin;
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.055.852 |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C28H37N5O7 | |
| Molar mass | 555.62 g/mol[1] |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
| |
Leu-enkephalin is an endogenous opioid peptide neurotransmitter with the amino acid sequence Tyr-Gly-Gly-Phe-Leu that is found naturally in the brains of many animals, including humans.[2][3] It is one of the two forms of enkephalin; the other is met-enkephalin.[2] The tyrosine residue at position 1 is thought to be analogous to the 3-hydroxyl group on morphine.[4] Leu-enkephalin has agonistic actions at both the μ- and δ-opioid receptors, with significantly greater preference for the latter. It has little to no effect on the κ-opioid receptor.[5][6]
A nasal spray formulation of leu-enkephalin (developmental code names NES-100, NM-0127, NM-127, PES-200; proposed brand name Envelta) is under development by Virpax Pharmaceuticals for the treatment of pain and post-traumatic stress disorder (PTSD).[7] As of November 2023, it is up to the preclinical stage of development for these indications.[7]